inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sotorasibsotorasib will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the CYP3A4 substrate for dosage modificationsSt John's WortSt John's Wort will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.sufentanil SLsufentanil SL, triazolam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tipranavirtipranavir increases levels of triazolam by decreasing metabolism. Contraindicated.tucatinibtucatinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.valerianvalerian and triazolam both increase sedation. Avoid or Use Alternate Drug.voxelotorvoxelotor will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.Monitor Closely (283)albuteroltriazolam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentaniltriazolam and alfentanil both increase sedation. Use Caution/Monitor.alprazolamalprazolam and triazolam both increase sedation. Use Caution/Monitor.amitriptylinetriazolam and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.amobarbital and triazolam both increase sedation. Use Caution/Monitor.amoxapinetriazolam and amoxapine both increase sedation. Use Caution/Monitor.apomorphinetriazolam and apomorphine both increase sedation. Use Caution/Monitor.aprepitantaprepitant will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.arformoteroltriazolam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazoletriazolam and aripiprazole both increase sedation. Use Caution/Monitor.armodafinilarmodafinil will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.triazolam increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.asenapineasenapine and triazolam both increase sedation. Use Caution/Monitor.atazanaviratazanavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.avapritinibavapritinib and triazolam both increase sedation. Use Caution/Monitor.azelastineazelastine and triazolam both increase sedation. Use Caution/Monitor.baclofentriazolam and baclofen both increase sedation. Use Caution/Monitor.belladonna and opiumtriazolam and belladonna and opium both increase sedation. Use Caution/Monitor.benperidoltriazolam and benperidol both increase sedation. Use Caution/Monitor.benzphetaminetriazolam increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.berotralstatberotralstat will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor or titrate substrate dose when berotralstat is coadministered with narrow therapeutic index drugs that are CYP3A substrates.bosentanbosentan will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.brexanolonebrexanolone, triazolam. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and triazolam both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and triazolam both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and triazolam both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and triazolam both increase sedation. Use Caution/Monitor.budesonidebudesonide will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.buprenorphinetriazolam and buprenorphine both increase sedation. Use Caution/Monitor.buprenorphine buccaltriazolam and buprenorphine buccal both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectiontriazolam increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.butabarbitalbutabarbital will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.butabarbital and triazolam both increase sedation. Use Caution/Monitor.butalbitalbutalbital will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.butalbital and triazolam both increase sedation. Use Caution/Monitor.butorphanoltriazolam and butorphanol both increase sedation. Use Caution/Monitor.caffeinetriazolam increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbinoxaminecarbinoxamine and triazolam both increase sedation. Use Caution/Monitor.carisoprodoltriazolam and carisoprodol both increase sedation. Use Caution/Monitor.cenobamatecenobamate, triazolam. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratetriazolam and chloral hydrate both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and triazolam both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and triazolam both increase sedation. Use Caution/Monitor.chlorpromazinetriazolam and chlorpromazine both increase sedation. Use Caution/Monitor.chlorzoxazonetriazolam and chlorzoxazone both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and triazolam both increase sedation. Use Caution/Monitor.clemastineclemastine and triazolam both increase sedation. Use Caution/Monitor.clobazamtriazolam, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipraminetriazolam and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and triazolam both increase sedation. Use Caution/Monitor.clonidineclonidine, triazolam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.clorazepateclorazepate and triazolam both increase sedation. Use Caution/Monitor.clozapinetriazolam and clozapine both increase sedation. Use Caution/Monitor.codeinetriazolam and codeine both increase sedation. Use Caution/Monitor.conivaptanconivaptan will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cortisonecortisone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.crizotinibcrizotinib increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crofelemercrofelemer increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizinecyclizine and triazolam both increase sedation. Use Caution/Monitor.cyclobenzaprinetriazolam and cyclobenzaprine both increase sedation. Use Caution/Monitor.cyclosporinecyclosporine will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cyproheptadinecyproheptadine and triazolam both increase sedation. Use Caution/Monitor.dabrafenibdabrafenib will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dantrolenetriazolam and dantrolene both increase sedation. Use Caution/Monitor.daridorexanttriazolam and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinibdasatinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.deferasiroxdeferasirox will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.desfluranedesflurane and triazolam both increase sedation. Use Caution/Monitor.desipraminetriazolam and desipramine both increase sedation. Use Caution/Monitor.deutetrabenazinetriazolam and deutetrabenazine both increase sedation. Use Caution/Monitor.dexamethasonedexamethasone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dexchlorpheniraminedexchlorpheniramine and triazolam both increase sedation. Use Caution/Monitor.dexfenfluraminetriazolam increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidinetriazolam and dexmedetomidine both increase sedation. Use Caution/Monitor.dexmethylphenidatetriazolam increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetaminetriazolam increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextromoramidetriazolam and dextromoramide both increase sedation. Use Caution/Monitor.DHEA, herbalDHEA, herbal will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.diamorphinetriazolam and diamorphine both increase sedation. Use Caution/Monitor.diazepamdiazepam and triazolam both increase sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, triazolam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.diethylpropiontriazolam increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and triazolam both increase sedation. Use Caution/Monitor.difenoxin hcltriazolam and difenoxin hcl both increase sedation. Use Caution/Monitor.diltiazemdiltiazem will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dimenhydrinatedimenhydrinate and triazolam both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and triazolam both increase sedation. Use Caution/Monitor.diphenoxylate hcltriazolam and diphenoxylate hcl both increase sedation. Use Caution/Monitor.dipipanonetriazolam and dipipanone both increase sedation. Use Caution/Monitor.disulfiramdisulfiram increases levels of triazolam by decreasing metabolism. Use Caution/Monitor.dobutaminetriazolam increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopaminetriazolam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexaminetriazolam increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepintriazolam and dosulepin both increase sedation. Use Caution/Monitor.doxepintriazolam and doxepin both increase sedation. Use Caution/Monitor.doxylaminetriazolam and doxylamine both increase sedation. Use Caution/Monitor.dronedaronedronedarone will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.droperidoltriazolam and droperidol both increase sedation. Use Caution/Monitor.duvelisibduvelisib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.efavirenzefavirenz will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.elagolixelagolix decreases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eluxadolineeluxadoline increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution when CYP3A substrates that have a narrow therapeutic index are coadministered with eluxadoline.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; consider benzodiazepine dose reduction.encorafenibencorafenib, triazolam. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.enzalutamideenzalutamide will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.epcoritamabepcoritamab, triazolam. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Epcoritamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .ephedrinetriazolam increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrinetriazolam increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrine racemictriazolam increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.esketamine intranasalesketamine intranasal, triazolam. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateeslicarbazepine acetate will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.estazolamestazolam and triazolam both increase sedation. Use Caution/Monitor.ethanoltriazolam and ethanol both increase sedation. Use Caution/Monitor.ethinylestradiolethinylestradiol will increase the level or effect of triazolam by Mechanism: decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines.etomidateetomidate and triazolam both increase sedation. Use Caution/Monitor.etravirineetravirine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fedratinibfedratinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fenfluraminetriazolam increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ferric maltolferric maltol, triazolam. Either increases levels of the other by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Coadministration of ferric maltol with certain oral medications may decrease the bioavailability of either ferric maltol and some oral drugs. For oral drugs where reductions in bioavailability may cause clinically significant effects on its safety or efficacy, separate administration of ferric maltol from these drugs. Duration of separation may depend on the absorption of the medication concomitantly administered (eg, time to peak concentration, whether the drug is an immediate or extended release product).flibanserintriazolam and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.fluconazolefluconazole will increase the level or effect of triazolam by affecting